Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Investigational New Drugs|September 24, 2022
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumabNobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 24, 2023
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita, et al.
Hepatology (Baltimore, Md.)|August 15, 2012
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinomaTokuzo Arao, Kazuomi Ueshima, Kazuko Matsumoto, et al.
Journal of Gastroenterology|March 7, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyTomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.
Cancers|June 2, 2021
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter StudyKaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto, et al.
JHEP Reports : Innovation in Hepatology|April 17, 2025
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCRisako Kohya, Goki Suda, Masatsugu Ohara, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
Journal of Gastroenterology|September 6, 2025
Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)Satoshi Kobayashi, Kohei Nakachi, Kouji Yamamoto, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Investigational New Drugs|September 24, 2022
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumabNobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 24, 2023
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita, et al.
Hepatology (Baltimore, Md.)|August 15, 2012
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinomaTokuzo Arao, Kazuomi Ueshima, Kazuko Matsumoto, et al.
Journal of Gastroenterology|March 7, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyTomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.
Cancers|June 2, 2021
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter StudyKaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto, et al.
JHEP Reports : Innovation in Hepatology|April 17, 2025
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCRisako Kohya, Goki Suda, Masatsugu Ohara, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
Journal of Gastroenterology|September 6, 2025
Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)Satoshi Kobayashi, Kohei Nakachi, Kouji Yamamoto, et al.
Pageof 15